In addition, veriparib (veliparib), a novel potent PARP-1 and PARP-2 inhibitor, had a 51% partial remission rate in the treatment group in a clinical phase II trial of breast cancer treatment, which was significantly higher than the standard chemotherapy group (26%) [89]. The gene discussed is PARP1; the disease is breast cancer.